Scorpion Therapeutics to Present Preclinical Proof-of-Concept Data for Highly Selective, Next-Generation Exon 20 Mutant EGFR Inhibitor at 34th EORTC-NCI-AACR Symposium

On October 12, 2022 Scorpion Therapeutics, Inc. ("Scorpion"), a pioneering oncology company redefining the frontier of precision medicine, reported that it will present preclinical proof-of-concept data for STX-721 in a poster session at the European Organisation for Research and Treatment of Cancer, the National Cancer Institute, and the American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("EORTC-NCI-AACR") Symposium 2022 in Barcelona, Spain, taking place October 26 – 28, 2022 (Press release, Scorpion Therapeutics, OCT 12, 2022, View Source [SID1234621969]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

STX-721 (formerly ST-5924) is Scorpion’s next-generation, orally delivered, small molecule designed with potential best-in-class selectivity for exon 20 insertion mutations in epidermal growth factor receptors ("EGFR"), a well-known, clinically validated oncogenic driver in non-small cell lung cancer ("NSCLC"). STX-721 is progressing through preclinical studies and Scorpion expects to submit an IND application to the U.S. Food and Drug Administration in 2023.

"We are excited to share foundational proof-of-concept data for STX-721, our next-generation EGFR inhibitor, which supports its potentially best-in-class product profile," said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion Therapeutics. "The Scorpion team developed this small molecule with the goal of delivering superior selectivity, as well as improved safety, tolerability and efficacy compared to currently marketed EGFR Exon 20 therapies and other drug candidates in development. We believe STX-721 could meaningfully improve the treatment of people living with EGFR exon 20-mutant NSCLC and look forward to advancing into clinical studies next year."